Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Ajinomoto Co. Inc.
DescriptionOral integrin alpha(4) (VLA-4; CD49D) antagonist
Molecular Target Integrin alpha(4) (VLA-4 ) (CD49D)
Mechanism of ActionIntegrin alpha(4) (VLA-4; CD49D) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation
PartnerKissei Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today